ROIV
Roivant Sciences Ltd. · Healthcare
Insiders sold $832.0M of Roivant Sciences Ltd. in the last 12 months and bought none
ROIV over the last year
ROIV after insider buys
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
108 insider filings since 2022, newest first
Eric Venker · President & Immunovant CEO
Epperly Melissa B, · Director
Eric Venker · President & Immunovant CEO
Epperly Melissa B, · Director
Meghan Fitzgerald · Director
Meghan Fitzgerald · Director
Eric Venker · President & Immunovant CEO
Mayukh Sukhatme · President and CIO
Mayukh Sukhatme · President and CIO
Eric Venker · President & Immunovant CEO
Meghan Fitzgerald · Director
Epperly Melissa B, · Director
Keith S Manchester · Director
Daniel Allen Gold · Director
QVT Financial LP · Director by Deputization
Mayukh Sukhatme · President and CIO
Eric Venker · President & Immunovant CEO
Eric Venker · Pres, Immunovant CEO
Eric Venker · Pres, Immunovant CEO
Matthew Gline · CEO
Meghan Fitzgerald · Director
Eric Venker · Pres, Immunovant CEO
Frank Torti · Pres, Vant Chair
Eric Venker · Pres, Immunovant CEO
Daniel Allen Gold · Director
Keith S Manchester · Director
Qvt Financial LP · Director by Deputization
Mayukh Sukhatme · President and CIO
Eric Venker · Pres, Immunovant CEO
Mayukh Sukhatme · President and CIO
Eric Venker · Pres, Immunovant CEO
Mayukh Sukhatme · President and CIO
Daniel Allen Gold · Director
Keith S Manchester · Director
Qvt Financial LP · Director by Deputization
Matthew Gline · CEO
Vivek Ramaswamy · 10% owner
Eric Venker · Pres, Immunovant CEO
Daniel Allen Gold · Director
Keith S Manchester · Director
Qvt Financial LP · Director by Deputization
Matthew Gline · CEO
Eric Venker · President and COO
Eric Venker · President and COO
Daniel Allen Gold · Director
Qvt Financial LP · Director by Deputization
Keith S Manchester · Director
Matthew Gline · CEO
Rakhi Kumar · Chief Accounting Officer
Eric Venker · President and COO
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.